Open AccessOpen-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Author(s) -
Hope S. Rugo,
Gerardo Umanzor,
Francisco Barrios,
Rosa H. Vasallo,
Marco A. Chivalan,
Suyapa Bejarano,
J. Ramírez,
Luis Fein,
Rubén Dario Kowalyszyn,
E Douglas Kramer,
Hui Wang,
Min-Fun Rudolf Kwan,
David L. Cutler
Publication year - 2022
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.21.02953
Subject(s) - medicine , paclitaxel , taxane , hazard ratio , clinical endpoint , metastatic breast cancer , breast cancer , adverse effect , premedication , gastroenterology , surgery , confidence interval , cancer , urology , randomized controlled trial
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom